Acyclovir is an agent used to treat infections caused by the herpes simplex virus (HSV). It is FDA approved to treat genital herpes and HSV encephalitis. Non-FDA approved indications are mucocutaneous HSV, herpes zoster (shingles), and varicella-zoster (chickenpox). Acyclovir is the first-line treatment for HSV encephalitis. Currently, there are no other medications indicated for the treatment of this condition.
Despite the long term use of acyclovir to treat HSV encephalitis, there has not been a systematic review regarding the efficacy of this disease/treatment combination. Current systematic reviews to address its safety and efficacy are currently ongoing, with the primary outcome being mortality rate. A secondary outcome measure is the quality of life.
HSV keratitis has been shown to respond to oral acyclovir and topical steroids in pediatric patients.
In patients with human immunodeficiency virus (HIV), acyclovir is sometimes used to treat eczema herpeticum. It is also used to prevent infections of the skin, eyes, nose, and mouth. Eczema herpeticum is rare but rapidly progressive if untreated. Those with extensive involvement, systemic symptoms, or decreased oral intake should undergo admission for intravenous acyclovir treatment. Also, acyclovir treats oral hairy leukoplakia.
Acyclovir has been proven useful in treating myelopathy secondary to varicella-zoster infection. In a small case series, researching patients from 1994 to 2014 with laboratory-confirmed varicella-zoster virus (VZV) and MRI confirmed myelopathy, marked improvement of symptoms was the outcome in most patients within two months.
Brachial plexus neuritis secondary to VZV infection and visceral disseminated VZV infection (characteristic features are abdominal and absence of skin lesions) has also responded to acyclovir, alleviating all symptoms.
In recipients of hematopoietic stem cell transplantation, herpes simplex virus and varicella-zoster reactivation may respond to treatment with acyclovir prophylaxis. Prophylactic use of acyclovir should be considered in HSV-1 and HSV-2-seropositive organ recipients, as well. Diseases from such viruses have decreased secondary to this intervention. However, a breakthrough infection may occur. Not surprisingly, HSV and VZV infection is not uncommon in patients that have discontinued acyclovir prophylaxis.
Another form of prophylactic acyclovir use is juvenile-onset recurrent respiratory papillomatosis. In a prospective observational study involving 21 patients, oral acyclovir was a postoperative adjuvant. It was shown to decrease the recurrence of papillomas and thus decrease the need for successive surgeries and associated operative risks.
VZV infections have many complications, including cerebellitis. Treating the source infection has been shown to decrease the complication burden as well. A 2019 case report, for instance, describes a patient presenting with truncal ataxia. After intravenous acyclovir treatment, the patient was free of neurologic disability and his cerebellitis.  Similarly, paresis secondary to dermatomal herpes zoster infections has been shown to respond to oral acyclovir; this is a rare complication of herpes zoster when the virus affects motor nerve fibers in addition to/instead of the dorsal root ganglion.
Acyclovir is an antiviral agent that incorporates itself into viral DNA. It inhibits DNA synthesis and viral replication after it is converted to acyclovir triphosphate by cellular enzymes. Acyclovir is a synthetic purine nucleoside analog that demonstrates in vitro and in vivo inhibitory activity against both herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus.
Acyclovir administration may be oral or intravenous.
For limited mucocutaneous lesions, acyclovir administration can be via the oral route. In cases in which there is disseminated, visceral, or CNS involvement, the acyclovir administration should be intravenous.
When taken orally, acyclovir may be taken with or without food 2 to 5 times a day for 5 to 10 days as well as up to 12 months to prevent outbreaks of genital herpes.
Intravenous administration should be done via IV infusion only, over 1 hour, at a constant rate to prevent renal damage. Medication should be in a diluted D5W solution or 0.9% NaCl to a final concentration of less than or equal to 7 mg/mL.
The following is a non-exhaustive list of dosing regimens:
Most commonly, patients experience malaise.
Less commonly, patients experience inflammation or phlebitis at the infusion site, nausea, vomiting, transaminitis, and rash (including Steven-Johnson syndrome) when taken intravenously. Rotating infusion sites and decreasing final infusion concentration less than 10 mg/mL can help prevent inflammation/phlebitis at the infusion site. Patients also may experience nausea, vomiting, diarrhea, headache when taken orally.
Least commonly, patients experience abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness and fatigue.
In certain pediatric patients, acyclovir has been shown to decrease hemoglobin levels and the absolute neutrophil count.
The only absolute contraindication to acyclovir is hypersensitivity.
Cautions include renal failure/impairment, immunocompromised host, potential risk of thrombotic thrombocytopenic purpura (TTP), and hemolytic uremic syndrome (HUS)).
Regarding pregnancy and lactation, acyclovir has been shown to cross the placenta. Acyclovir's manufacturer recommends caution with use during pregnancy as well as only using it when necessary and indicated, as there have only been a few studies conducted. Specifically, cases of HSV hepatitis have received treatment during pregnancy. Although rare, this condition can become disseminated and fatal in pregnant patients. Although all 56 patients studied had transaminitis, only 18.2% had a vesicular rash. For patients that were treated with acyclovir empirically, it conferred no risks to the fetus. Acyclovir also has been shown to enter breast milk but is generally considered compatible with breastfeeding.
Patients should be monitored for adverse effects such as malaise, inflammation or phlebitis at infusion site, nausea, vomiting, rash (including Steven-Johnson syndrome), transaminitis, nausea, vomiting, diarrhea, headache, abdominal pain, aggression/confusion, agitation, alopecia, anaphylaxis, anemia, angioedema, anorexia, ataxia, coma, disseminated intravascular coagulation (DIC), dizziness and fatigue.
Acute kidney injury (AKI) is the most significant side effect of parenteral acyclovir administration. The incidence of AKI is comparable to other nephrotoxic medications such as aminoglycosides. Patients with CKD are at higher risk. Dose adjustment of acyclovir for ideal body weight and baseline renal function is imperative. A study regarding the pharmacokinetics of acyclovir demonstrated that a patient's glomerular filtration and tubular secretion contribute to its renal excretion.
Also, a recent retrospective case-control study over four years showed a statistically significant association between obesity and nephrotoxicity (odds ratio 3.2, 95% CI 1.19 to 8.67). Similarly, and not surprisingly, researchers observed a similar association between those receiving concomitant vancomycin (odds ratio 4.73, 95% CI, 1.57 to 14.25). Appropriate cautions are necessary when administering intravenous acyclovir to such higher-risk patients.
Administering intravenous acyclovir requires interdisciplinary effort and communication. It is not a benign drug, having potential side effects such as phlebitis, hypersensitivity, and AKI. Therefore, pharmacists, physicians, and nurses must work together to achieve adequate and non-toxic dosing. Physicians (MDs, DOs, NPs, PAs) will make the initial decision to use acyclovir. Dose adjustments for ideal body weight and baseline renal function are necessary, and the pharmacist should coordinate this with nursing for inpatients. Also, patients must undergo monitoring for signs/symptoms of hypersensitivity and phlebitis, specifically at the infusion site; this is where nursing will be best positioned to inform the rest of the healthcare team should there be any issues of concern. Interprofessional teamwork between each healthcare provider for a patient can help minimize and prevent the adverse effects of intravenous administration of acyclovir. [Level V]
|||Ahronowitz I,Fox LP, Herpes zoster in hospitalized adults: Practice gaps, new evidence, and remaining questions. Journal of the American Academy of Dermatology. 2018 Jan; [PubMed PMID: 29146146]|
|||Gori N,Caldarola G,de Simone C,Moretta G,Peris K, Annular elastolytic giant cell granuloma following Herpes Zoster infection. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 Apr 13; [PubMed PMID: 30980767]|
|||Stahl JP,Mailles A, Herpes simplex virus encephalitis update. Current opinion in infectious diseases. 2019 Jun [PubMed PMID: 30921087]|
|||Wang W,Ji M, Efficacy of acyclovir for herpes simplex encephalitis: A protocol for a systematic review of randomized controlled trial. Medicine. 2019 Apr [PubMed PMID: 30985731]|
|||Bodack MI, Case Series: Pediatric Herpes Simplex Keratitis. Optometry and vision science : official publication of the American Academy of Optometry. 2019 Mar [PubMed PMID: 30801497]|
|||Ozcan A,Kahale K,Nguyen D, An 8-Month-Old Girl With Vesicular Rash. Global pediatric health. 2019 [PubMed PMID: 30956997]|
|||Ljubojevi? Had�avdi? S,Kova?evi? M,Skerlev M,Zekan �, Genital Herpes Zoster as Possible Indicator of HIV Infection. Acta dermatovenerologica Croatica : ADC. 2018 Dec; [PubMed PMID: 30665486]|
|||Frimpong P,Amponsah EK,Abebrese J,Kim SM, Oral manifestations and their correlation to baseline CD4 count of HIV/AIDS patients in Ghana. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 2017 Feb; [PubMed PMID: 28280707]|
|||Farhat N,Daoud S,Hdiji O,Sakka S,Damak M,Mhiri C, Myelopathy after zoster virus infection in immunocompetent patients: A case series. The journal of spinal cord medicine. 2019 Apr 23 [PubMed PMID: 31013469]|
|||Lee S,Tsukasaki H,Yamauchi T, Visceral disseminated varicella zoster virus infection with brachial plexus neuritis detected by fluorodeoxyglucose positron emission tomography and computed tomography. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2019 Mar 14 [PubMed PMID: 30879980]|
|||Lee DH,Zuckerman RA, Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical transplantation. 2019 Mar 12 [PubMed PMID: 30859647]|
|||Dadwal SS, Herpes Virus Infections Other than Cytomegalovirus in the Recipients of Hematopoietic Stem Cell Transplantation. Infectious disease clinics of North America. 2019 Jun [PubMed PMID: 31005137]|
|||Mitra S,Das A,Ghosh D,Sengupta A, Postoperative Systemic Acyclovir in Juvenile-Onset Recurrent Respiratory Papillomatosis: The Outcome. Ear, nose, & throat journal. 2019 Jan [PubMed PMID: 30834790]|
|||Cross CP,English SW,Krause MA,Zalewski NL, Acute truncal ataxia in a healthy adult with varicella zoster virus cerebellitis: A case report and literature review. Journal of the neurological sciences. 2019 May 15 [PubMed PMID: 30981122]|
|||Yu YH,Lin Y,Sun PJ, Segmental zoster abdominal paresis mimicking an abdominal hernia: A case report and literature review. Medicine. 2019 Apr [PubMed PMID: 30985652]|
|||Kukhanova MK,Korovina AN,Kochetkov SN, Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry. Biokhimiia. 2014 Dec; [PubMed PMID: 25749169]|
|||Le A,Patel S, Extravasation of Noncytotoxic Drugs: A Review of the Literature. The Annals of pharmacotherapy. 2014 Jul; [PubMed PMID: 24714850]|
|||Yorulmaz A,Sahin EB,Sener M,Kulcu Cakmak S, Acyclovir-induced bullous reaction in a patient with metastatic breast cancer. Cutaneous and ocular toxicology. 2017 Mar; [PubMed PMID: 26911608]|
|||McCormack AL,Rabie N,Whittemore B,Murphy T,Sitler C,Magann E, HSV Hepatitis in Pregnancy: A Review of the Literature. Obstetrical & gynecological survey. 2019 Feb [PubMed PMID: 30756123]|
|||Charlier C,Le Mercier D,Salomon LJ,Ville Y,Kermorvant-Duchemin E,Frange P,Postaire M,Lortholary O,Lecuit M,Leruez-Ville M, [Varicella-zoster virus and pregnancy]. Presse medicale (Paris, France : 1983). 2014 Jun; [PubMed PMID: 24863663]|
|||Ryan L,Heed A,Foster J,Valappil M,Schmid ML,Duncan CJA, Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2018 Sep; [PubMed PMID: 30048817]|
|||de Miranda P,Whitley RJ,Blum MR,Keeney RE,Barton N,Cocchetto DM,Good S,Hemstreet GP 3rd,Kirk LE,Page DA,Elion GB, Acyclovir kinetics after intravenous infusion. Clinical pharmacology and therapeutics. 1979 Dec [PubMed PMID: 227639]|
|||Barber KE,Wagner JL,Stover KR, Impact of Obesity on Acyclovir-Induced Nephrotoxicity. Open forum infectious diseases. 2019 Apr [PubMed PMID: 31024972]|